1. Clinical Overview
Satranidazole is a second-generation 5-nitroimidazole derivative antimicrobial and antiprotozoal agent. It is structurally related to metronidazole and tinidazole but exhibits a broader spectrum of activity, improved pharmacokinetics, and a better safety profile, particularly regarding neurological side effects. It is widely used in India for the treatment of amoebiasis, giardiasis, trichomoniasis, and anaerobic bacterial infections.
| Onset | Duration | Bioavailability |
|---|---|---|
| Peak plasma concentration (Tmax) is achieved within 2-4 hours of oral administration. | Effective therapeutic concentrations are maintained for approximately 12-24 hours, supporting a twice-daily or once-daily dosing regimen. | Approximately 85-90% following oral administration. |
2. Mechanism of Action
Satranidazole is a prodrug. Its nitro group is reduced intracellularly by low-redox potential electron transport proteins (ferredoxin or flavodoxin) found in anaerobic microorganisms and protozoa. This reduction generates cytotoxic, short-lived nitro radical anions that cause DNA strand breaks, inhibition of nucleic acid synthesis, and ultimately cell death.
3. Indications & Uses
- Intestinal amoebiasis (Entamoeba histolytica)
- Giardiasis (Giardia lamblia)
- Trichomoniasis (Trichomonas vaginalis)
- Anaerobic bacterial infections (e.g., Bacteroides spp., Clostridium spp.)
4. Dosage & Administration
Adult Dosage: Amoebiasis/Giardiasis/Anaerobic Infections: 300 mg twice daily for 5-7 days. Trichomoniasis: A single dose of 2 grams (four 500mg tablets) OR 300 mg twice daily for 7 days.
Administration: To be taken orally, after food to minimize gastrointestinal upset. Tablet should be swallowed whole with a full glass of water. Do not crush or chew.
5. Side Effects
Common side effects may include:
- Nausea
- Metallic/bitter taste in mouth
- Headache
- Dizziness
- Abdominal discomfort
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Warfarin and other Coumarin Anticoagulants | Satranidazole may potentiate anticoagulant effect, increasing risk of bleeding. | Major |
| Lithium | May increase lithium serum levels and risk of toxicity. | Major |
| Phenobarbital, Phenytoin | Enzyme inducers may reduce plasma concentration of satranidazole. | Moderate |
| Cimetidine | May increase plasma concentration of satranidazole by inhibiting metabolism. | Moderate |
| Alcohol | Risk of a disulfiram-like reaction (flushing, tachycardia, nausea) is low but possible. Avoidance is still recommended. | Moderate |
7. Patient Counselling
- DO complete the full course of treatment, even if you feel better.
- DO take the medicine after food.
- DO inform your doctor if you are pregnant, planning pregnancy, or breastfeeding.
- DO NOT consume alcohol during treatment and for at least 72 hours after the last dose.
- DO NOT drive or operate heavy machinery if you experience dizziness.
8. Toxicology & Storage
Overdose: Nausea, vomiting, ataxia, seizures, and peripheral neuropathy. No specific organ failure pattern is consistently reported.
Storage: Store below 30°C, in a cool, dry place. Protect from light and moisture. Keep out of reach of children.